A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease

Hypertension

Volumn 61, Issue 1, 2013, Pages 82-88

  Rahman, Mahboob ^a   Greene, Tom ^b   Phillips, Robert A ^c   Agodoa, Lawrence Y ^d   Bakris, George L ^e   Charleston, Jeanne ^f   Contreras, Gabriel ^g   Gabbai, Francis ^h   Hiremath, Leena ⁱ   Jamerson, Kenneth ^j   Kendrick, Cynthia ^k   Kusek, John W ^p   Lash, James P ^l   Lea, Janice ^m   Miller, Edgar R ^f   Rostand, Stephen ⁿ   Toto, Robert ^o   Wang, Xulei ^k   Wright, Jackson T ^a   Appel, Lawrence J ^f  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^m EMORY UNIVERSITY   (United States)

ⁿ UNIVERSITY OF ALABAMA   (United States)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p NONE

more..

Author keywords

chronic kidney disease; hypertension; nocturnal blood pressure

Indexed keywords

DILTIAZEM; HYDRALAZINE; RAMIPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NEGRO; NOCTURNAL BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DILTIAZEM; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYDRALAZINE; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84871617630     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.200477     Document Type: Article

References (33)

1. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268:456-467.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. (Pubitemid 350074801)
3. Appel LJ, Wright JT Jr, Greene T, et al African American Study of Kidney Disease and Hypertension Collaborative Research Group. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168:832-839. (Pubitemid 351620085)
4. Feldman HI, Appel LJ, Chertow GM, et al Chronic Renal Insuffciency Cohort (CRIC) Study Investigators. The Chronic Renal Insuffciency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol. 2003;14(7 suppl 2):S148-S153. (Pubitemid 36750511)
5. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat.Rev.Nephrol. 2009; 5:677-689.
6. Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr.Opin.Nephrol.Hypertens. 2009; 18:507-512.
7. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA; African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53:20-27.
8. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation. 1993;88:986-992. (Pubitemid 23264014)
9. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specifc cardiovascular events in hypertension. Hypertension. 2008;51:55-61. (Pubitemid 350307104)
10. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546. (Pubitemid 29380290)
11. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:1175-1180.
12. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797-805. (Pubitemid 34988338)
13. Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboli P, Conte G, Gabbai FB, De Nicola L. Prognostic role of ambulatory blood pressure measurement in patients with nondialy-sis chronic kidney disease. Arch Intern Med. 2011;171:1090-1098.
14. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration time-dependent effects of valsar-tan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003;42:283-290. (Pubitemid 37093474)
15. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Fontao MJ, López JE. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int. 2004;21:277-296. (Pubitemid 39014625)
16. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of α-adrenergic blocker, doxazosin: results from the HALT study. Hypertension. 2000;35:787-794. (Pubitemid 30165327)
17. White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol. 1998;81:424-431. (Pubitemid 28099532)
18. White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J. 2004;148:628-634. (Pubitemid 39349382)
19. Appel LJ, Middleton J, Miller ER 3rd, et al. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14(7 suppl 2):S166-S172. (Pubitemid 36750513)
20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161. (Pubitemid 40066429)
21. Li Y, Boggia J, Thijs L, et al; International Database on Ambulatory Blood Pressure Monitoring in relation to Cardiovascular Outcomes Investigators. Is blood pressure during the night more predictive of cardiovascular outcome than during the day? Blood Press Monit. 2008;13:145-147.
22. Fan HQ, Li Y, Thijs L, et al International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036-2045.
23. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801. (Pubitemid 24363980)
24. Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med. 2000;17: 360-364. (Pubitemid 30353800)
25. Townsend RR, Ford V. Ambulatory blood pressure monitoring: coming of age in nephrology. J Am Soc Nephrol. 1996;7:2279-2287. (Pubitemid 27465932)
26. Peterson GE, de Backer T, Gabriel A, Ilic V, Vagaonescu T, Appel LJ, Contreras G, Kendrick C, Rostand S, Phillips RA; African American Study of Kidney Disease Investigators. Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension. 2007;50:1033-1039. (Pubitemid 350172924)
27. Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Pogue V, Wright JT, Lipkowitz M, Phillips RA AASK study group. ambulatory blood pressure (ABP) as a predictor of renal (R) and cardiovascular (CV) outcomes in CKD patients with masked and sustained hypertension. results from the cohort phase of the African American Study of Kidney Disease and Hypertension (AASK). Clin J Am Soc Nephrol. 2012 Aug 30. [Epub ahead of print]
28. Ishikawa J, Shimizu M, Hoshide S, Eguchi K, Pickering TG, Shimada K, Kario K. Cardiovascular risks of dipping status and chronic kidney disease in elderly Japanese hypertensive patients. J Clin Hypertens (Greenwich). 2008;10:787-794.
29. Hermida RC, Ayala DE, Mojon A, Fernandez Jr. Infuence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010; 27:1629-1651.
30. Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis. 2007;50:908-917. (Pubitemid 350122805)
31. Hermida RC, Ayala DE, Mojón A, Fernández Jr. Bedtime dosing of anti-hypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313-2321.
32. Adeseun GA, Rosas SE. The impact of obstructive sleep apnea on chronic kidney disease. Curr Hypertens Rep. 2010;12:378-383.
33. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res. 2010;33:515-520.